Schizophrenia, Schizoaffective Disorder
Conditions
Keywords
schizophrenia, adherence
Brief summary
This prospective study examines the differences among several measures of adherence to antipsychotic medications in outpatients with schizophrenia. Adherence is assessed by using self-report, physician report, pill count and electronic monitoring. The rates of adherence/non-adherence with various tools will be manifested. The association between antipsychotic adherence/non-adherence and various clinical status, including psychotic symptoms, depressive symptoms, side effects, neurocognitive function and insight are analyzed. Participants are assessed at baseline during a visit to their outpatient clinic and followed up for 8 weeks.
Interventions
MEMS is a medication vial cap that electronically records the date and time of bottle opening.
Sponsors
Korea University Guro Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Ability to provide written informed consent 2. Male or female, aged from 20 to 65 years 3. Clinician rendered diagnosis of schizophrenia or schizoaffective disorder documented by a checklist of Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV) criteria 4. Currently taking a single oral antipsychotic (e.g., Quetiapine, Risperidone, Olanzapine, or Amisulpride). 5. Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropine (HCG) test at enrolment 6. Outpatient status, with psychiatric hospitalization or psychiatric emergency room visit within the previous 2 years and no hospitalizations within 3 months 7. mild to moderate symptom checked by CGI-S (less than score 4) 8. Able to understand and comply with the requirements of the study
Exclusion criteria
1. Any DSM-IV Axis I disorder not defined in the inclusion criteria 2. Presence of a co-morbid diagnosis that might influence outcome measures (e.g., mental retardation) 3. Alcohol or substance dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria 4. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others 5. Pregnancy or lactation 6. Evidence of hypersensitivity to Quetiapine or other antipsychotics used in the study 7. Use of any cytochrome P450 inhibitors or inducers in the 14 days preceding enrolment 8. Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation 9. use of pillbox 10. Treatment with Clozapine (because of its unique monitoring guidelines) 11. Administration of electroconvulsive therapy (ECT) in the last 6 months 12. Unstable or inadequately treated medical condition such as heart, liver, kidney, or lung disease, or a seizure disorder 13. Involvement in the planning and conduct of the other study. 14. Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence is assessed by four methods including Medication Event Monitoring System | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Various factors that have been identified as influencing adherence | 8 weeks |
Countries
South Korea
Outcome results
None listed